Randomized, multicenter, open-labeled, two-arm parallel group trial of pitavastatin 2 mg OD for reducing the risk of major cardiovascular events in patients with clustering cardiovascular risk factors

Korea Centers for Disease Control and Prevention0 个研究点目标入组 2,062 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•1. Acquisition of consent form
•2. Total cholesterol level of less than 220mg/dl
•Should have at least one of categories listed in the item 3. or 4.
•3. Clearly diagnosed as diabetes and should have at least two of those listed as follows;
•- Age ; male 45YO or more, female 55YO or more
•- Current smoker
•- Diagnosed as hypertension
•- Low HDL cholesterol levels <40 mg/dl
•- Abdominal obesity (male; 90 cm or more, female; 85 cm or more of waist circumferences)
•4. Non-diabetics, but calculated 10-year-risk for cardiovascular disease (offered by NCEP-III guideline) equals or more than 20 % and diagnosed as metabolic syndrome.

•1. Age of 80 YO or more
•2. History of uncontrolled endocrinologic diseases; such as hypothyroidism, hypopituitarism, or others.
•3. Pregnancy
•4. Azotemia
•5. HIV positive
•6. Abnormal serum levels of liver (AST, ALT) and muscle (CK) enzymes
•7. History of neoplasm
•8. History of overt cardiovascular disease
•9. Hear failure
•10. Triglyceride levels > 400mg/dl
•11. Total cholesterol levels < 150mg/dl
•12. HbA1C levels > 11.0%

发起方

Korea Centers for Disease Control and Prevention